The Lind Partners

At Lind, they understand the challenges faced by management teams of growing companies. By upholding their mission to be a responsible investor and a reliable financial partner, they have built a reputation as a leading provider of growth capital to the small- and mid-cap sector. The Lind Partners is a New York-based alternative asset management firm that manages a family of institutional investment funds focused on small- and mid-cap publicly traded companies with an emphasis on Australia, Canada and the United Kingdom. Since 2009, the core team at Lind has worked on over 75 direct investments with a total transaction value in excess of $550 million.

Valliere, Phillip

Managing Director

13 past transactions

HUB Security

Post in 2023
HUB Security was established in 2017 by veterans of the 8200 and 81 elite intelligence units of the Israeli Defense Forces. The company specializes in unique Cyber Security solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity professional services worldwide.

PaxMedica

Post in 2023
PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. The company's programs are focused on two of the world’s most challenging conditions Founded in 2018, the company is based in Tarrytown, New York.

Bragg Gaming

Post in 2022
Bragg Gaming Group is a content-driven iGaming technology provider that provides proprietary and exclusive content as well as technology to online and land-based gaming operators. It provides high-performing, data-driven, and passionately crafted casino gaming titles from Wild Streak Gaming, Spin Games, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. Its proprietary content portfolio is supplemented by a selection of Powered By Bragg titles from carefully selected studio partners: games built on Bragg remote games server (Bragg RGS) technology, distributed via the Bragg Hub content delivery platform, and available exclusively to Bragg's customers. All content delivered through the Bragg Hub is managed from a single back-office and is backed up by powerful data analytics tools and Bragg's Fuze player engagement toolset.

Seelos Therapeutics

Post in 2021
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.

Appili Therapeutics

Post in 2021
Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives.
Magnis Energy Technologies produces and conducts research on lithium-ion batteries. The production of lithium-ion batteries, which is essential for the use of electric mobility and energy storage, is carried out by a corporation with an ASX listing. They work together with C4V, a technical partner that has created anode and cathode battery materials that are protected by patents. Magnis also has a minority stake in C4V and has licensed their anode processing technology exclusively with the goal of producing high performance anode materials using ultra-high purity natural flake graphite from Magnis' Nachu Graphite Project in Tanzania. Magnis' Nachu project in Tanzania produces high-quality natural flake graphite concentrate, which is in high demand in the anode material market for lithium-ion batteries. Because of its distinct graphitic crystal structure and low impurities, it does not require expensive and environmentally hazardous chemicals for purification.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

COMSovereign

Post in 2021
COMSovereign is a pure-play enabler of 5G connectivity and data transmission systems. The company has assembled a portfolio of industry-leading, disruptive, communications, and power technologies as well as niche companies capable of rapid integration and expansion. It focuses on businesses or products to which it can apply new and unique spectral efficiency capabilities including signal modulations, antenna, software, hardware, and firmware technologies. COMSovereign enables connectivity across the entire data transmission spectrum.

Boxlight

Post in 2019
Boxlight is an education technology company that provides technology solutions such as digital signage, classroom audio, and other related services for the global learning market. The company aims to improve learning and engagement in classrooms and to help educators enhance student outcomes, by developing the products they need. It also develops, sells, and services its integrated, interactive solution suite including software, classroom technologies, professional development, and support services.

Noxopharm

Post in 2019
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.
Avalon Advanced Materials specializes in critical metals and minerals with growing demand in new technology. They focus on rare metals and minerals, including lithium, tantalum, niobium, cesium, indium, gallium, germanium, rare earth elements, yttrium, and zirconium.

Vamp

Venture Round in 2017
Vamp is a global influencer marketing and content creation platform that connects brands like Adobe, Estée Lauder and Nestlé to its vetted community of creators, for beautifully effective campaigns. A trusted Business Partner of Facebook, Creative Marketing Partner of TikTok and Creative Partner of YouTube, Vamp provides brands with an omni-channel, self-serve solution for reaching their customers on social media. Vamp’s creators deliver premium, mobile-first content, turning marketing goals into reality. Whether it’s published in social feeds, transformed into ad-ready units or placed into targeted paid media campaigns, their content outperforms industry standards. Founded in Australia in 2015, Vamp now has global presence having completed campaigns in 65 countries. It has teams in Sydney, Hong Kong, Singapore, Dubai, London, Jakarta and Tokyo.

Identitii

Venture Round in 2017
Identitii is using tokenisation to connect banks and businesses with the data they need to process, reconcile and report on payments, reducing last mile hold ups. It is helping customers know when they will be paid, by whom and what for, putting them back in control of the payment process.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.